MedTrace Logo

Dexmedetomidine and Esmolol Early Post Operative Cognitive Dysfunction

NCT03892512 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2019-03-27

No results posted yet for this study

Summary

Dexmedetomidine is a highly selective α2adrenoceptor agonist recently introduced to anesthesia that produces dose dependent sedation, anxiolysis, and analgesia (involving spinal and supraspinal sites) without respiratory depression.

From a pharmacokinetic perspective,dexmedetomidine has a half life of nearly 2 hours, duration of action of nearly 4 hour, and thus, a side effect profile that is shorter in duration than clonidine.

Esmolol is a cardioselective beta₁ receptor blocker with rapid onset, a very short duration of action (elimination half-life is approximately 9 minutes) , and no significant intrinsic sympathomimetic or membrane stabilising activity at therapeutic dosages

Conditions

  • Cognitive Dysfunction

Interventions

DRUG

Esmolol Hydrochloride

Patients will receive hypotensive anesthesia via I .V infusion with esmolol ( Esmolol Hydrochloride )

DRUG

Dexmedetomidine

The Patients will receive hypotensive anesthesia via I .V infusion with dexmedetomidine (Percedex )

Sponsors & Collaborators

  • Beni-Suef University

    lead OTHER

Principal Investigators

  • Samaa ak Rashwan, MD · Assisstant proffesor of anesthesia

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-30
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03892512 on ClinicalTrials.gov